Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
A health ministry panel has agreed that Japan should add a high-dose influenza vaccine for older adults, Sanofi’s Efluelda, to the national immunization program (NIP), citing sufficient efficacy, safety, and cost-effectiveness. At an October 22 meeting, the vaccine evaluation working…
To read the full story
Related Article
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
- Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over
November 21, 2025
- Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
February 21, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
REGULATORY
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
- Growth Strategy Council WG Weighs Incentives for Clinical Trial Sites
March 17, 2026
- Gaku Hashimoto to Return as Skipper of LDP Team on Drug Innovation
March 17, 2026
- Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
March 16, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…